Introduction {#S5}
============

Autosomal dominant Alzheimer's disease (ADAD) is a rare, completely penetrant form of Alzheimer's disease that typically presents at a much earlier age than sporadic forms of Alzheimer's disease. Despite its rarity, ADAD has been used as a model for understanding pathological processes and developing potential therapies for sporadic Alzheimer's disease due to similarities in both clinical course and pathophysiology (for a comprehensive review, see Bateman et al, 2011^[@R1]^). Although the majority of carriers of symptomatic mutations in the amyloid precursor protein (*APP*), presenilin-1 (*PSEN1*), or presenilin-2 (*PSEN2*) present with early amnestic symptoms^[@R2]^ similar to those with sporadic Alzheimer's disease, a significant portion of individuals with ADAD have been reported to exhibit additional behavioral and neurologic deficits, such as seizures, myoclonus, spastic paraparesis, or visual disturbances, with remarkable diversity in age of onset, clinical presentation, and rate of progression^[@R1],[@R3]-[@R5]^. The location of mutations within genes has also been shown to affect pathophysiology and age of onset, as is the case for presenilin-1 mutations before and after codon 200^[@R6]^. As a consequence of the rarity of ADAD and the reported variability in presentation, it has been difficult to estimate the prevalence of neurological manifestations of ADAD mutation carriers as a group.

To this end, we aimed to better clarify the incidence and prevalence rates of non-amnestic manifestations of ADAD from a prospective global observational ADAD study-- the Dominantly Inherited Alzheimer's Network Observational Study (DIAN--OBS) -- and also individual level data of symptomatic cases extracted from 189 published reports. Additionally, we aimed to assess relationships of these clinical manifestations with the age of symptom onset and the location of ADAD mutations within affected genes as this could provide important information on the pathophysiology of ADAD mutations. The DIAN--OBS findings complement the existing published literature by contributing uniform and extensive assessments in a prospective cohort with mild to moderate AD to the literature reports of pedigrees clinically followed to more advanced stages of dementia. The results of this work may help to clarify the clinical presentations of ADAD and hold implications for the structure and function of the presenilin proteins and APP.

Methods {#S6}
=======

The DIAN study is reviewed and approved by all participating sites Institutional/Ethical Review Boards (IRB). All participants (and as appropriate their legally authorized representatives) sign IRB-approved DIAN consent forms that include a statement informing participants that deidentified data will be shared with authorized investigators for future research following guidelines for preserving confidentiality through coded identifiers.

Literature database {#S7}
-------------------

In an expansion of our previously reported ADAD meta-analysis dataset^[@R7]^, clinical data on 1335 carriers of 183 known pathogenic mutations in *APP, PSEN1*, and *PSEN2* was collected from publications cited in the Alzheimer's Disease/Frontotemporal Dementia Mutation Database, the Alzheimer Research Forum database, and PubMed search results using the terms "dominant Alzheimer", "dominant AD", "ADAD", "presenilin", "PSEN1", "PSEN2", and "APP". Genotype information, pedigree information, ages of onset and death, clinical descriptions of the disease course and symptomatology, and pathological findings for each affected individual were recorded, when available. Demographic characteristics of this population are provided in [table 1](#T1){ref-type="table"}.

DIAN database {#S8}
-------------

Analyses were performed on DIAN datafreeze 8. Participants in the DIAN observational study include families of carriers of mutations causing ADAD in *APP, PSEN1* or *PSEN2*^[@R8]^. Per standard DIAN protocols, each study participant and a collateral source underwent semi-structured interviews that included detailed demographics, medical history, and family history. All study staff underwent audiotape recordings of the clinical assessments at the beginning of the study and then every 10^th^ participant to ensure compliance with the protocol and increase inter-rater reliability. In addition, each participant completed a physical and neurological examination conducted by a clinical evaluator who was blinded to the participant's mutation status. A total of 107 individuals were considered to be symptomatic at time of analysis, based upon having both a Clinical Dementia Rating sum of boxes (CDRsb) score^[@R9]^ greater than 0 and a known pathogenic ADAD mutation as confirmed by genetic testing using methods previously described^[@R10],[@R11]^. Using data from these individuals, we constructed a database including age, gender, mutated gene, mutation type (including specific amino acid change of the mutation, eg, PSEN1 E280A), *APOE* genotype, family history, medical history, list of medications, age of onset evaluation, physical exam, neurological exam, CDR (including supplemental boxes for behavior and language), Functional Activities Questionnaire (FAQ), Mini-Mental Status Exam (MMSE), Geriatric Depression Scale (GDS), Unified Parkinson's disease rating scale (UPDRS), vascular contributions to dementia/or history of stroke (Hachinski Ischemic Score, (HIS), clinical judgment of symptoms, clinician diagnosis, and psychometric battery summary.

Individuals were assessed for the presence of non-amnestic cognitive or non-cognitive symptoms using neurological exams conducted during their initial visit and each visit thereafter and sections from the National Alzheimer's Coordinating Center's Uniform Data Set (UDS)^[@R12]^, paying specific attention to the health history (UDS A5, B2), UPDRS (UDS B3), and clinician judgment of symptoms (UDS B9). UPDRS scores were calculated based on review of performance in each of 27 motor domains (eg, body bradykinesia, facial expressiveness, gait, etc), with a maximum possible score of 108. If an individual exhibited a specific symptom during any visit, that symptom was marked as "present". Demographic characteristics of this population are provided in [table 1](#T1){ref-type="table"}. A list of descriptions of the exact process used to extract this data is provided in [supplemental table 1](#SD1){ref-type="supplementary-material"}.

Subject selection {#S9}
-----------------

Only symptomatic individuals were studied. We included a total of 753 individuals from literature reports and 107 from the DIAN Observational Study in our analysis ([table 1](#T1){ref-type="table"}). In the literature group, individuals were designated as symptomatic by the authors of the publication in which they are found, and their age of symptom onset was recorded when available. Length of follow up time in this group is defined as the time from age of onset until the individual either died or was lost to follow up. Age of onset was determined by clinician judgment as the age at which the individual began to exhibit cognitive decline, and years of follow up is calculated by subtracting the individual's age of onset from their age at the latest visit. Those *APP* mutations with predominant cerebral amyloid angiopathy (CAA), ie, the Dutch mutation, were not included in this analysis as they may be associated with less uniform pathology.

Statistical analysis {#S10}
--------------------

For the comparison between autosomal dominant and DIAN, we calculated the prevalence of a group of cognitive and non-cognitive symptoms in the literature database and the DIAN cohort, respectively. To compare symptom prevalence between mutations found in *APP, PSEN1*, and *PSEN2*, we constructed a generalized linear mixed model treating the mutated gene as a fixed effect, and including a unique identifier for family pedigree as a random effect, in order to take into account the impact of familial genetics. Age of onset was also included as a fixed effect. We did not specifically analyze the effect of *APOE* ε4 carrier status on disease course due to limitations in sample size. Additionally, we directly compared the symptom prevalence in carriers of *PSEN1* mutations before and after codon 200^[@R6]^. We also explored the relationship between clinical severity as measured by CDR-SB and the frequency of clinical features in the DIAN--OBS group but were unable to perform a similar exploration in the literature group due to clinical ratings at time of non-amnestic symptoms not being reported in most.

Role of the funding source {#S11}
--------------------------

Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer's Network (DIAN, UF1 AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), The MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1) and NIHR Queen Square Dementia Biomedical Research Unit. This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. The corresponding author had full access to the data in the study and had final responsibility for the decision to submit for publication.

Results {#S12}
=======

Compared to the literature group, the DIAN Observation Study cohort has a significantly earlier average age of onset and shorter average follow up time ([Table 1](#T1){ref-type="table"}). Overall, 36 of the 107 individuals in the DIAN--OBS displayed one or more abnormality on the neurological exam at any point during the time they were followed ([figure 1](#F1){ref-type="fig"}). Significantly higher rates of cognitive symptoms were noted in the DIAN--OBS group than the literature group, including aphasia (57/107 (53%) vs. 173/753 (23%), p \< 0·0001), visual agnosia (59/107 (55%) vs. 42/753 (5·6%), p \< 0·0001), and behavioral/personality changes (65/107 (61%) vs. 239/753 (32%), p \< 0·0001) ([table 2](#T2){ref-type="table"}). In contrast, motor symptoms such as myoclonus (10/107 (9·3%) vs. 146/753 (19%), p = 0·0117) and recent/active seizures (3/107 (2·8%) vs. 153/753 (20·3%), p \< 0·0001) were less common in the DIAN--OBS group compared to the literature group; corticobulbar deficits were marginally less common in DIAN--OBS (3/107 (2·8%) vs. 61/753 (8·1%), p= 0·051). The rate of cerebellar ataxia was higher in the DIAN--OBS group than the literature group (16/107 (15%) vs. 23/753 (3·1%), p \< 0·0001). The rates of parkinsonism were similar between DIAN--OBS and the literature group, (12/107 (11%) vs. 94/753 (12%), p = 0·71). Of the twelve individuals in DIAN who displayed parkinsonian symptoms, eleven were mildly symptomatic (UPDRS total score \< 36), and one was moderately symptomatic with a score of 58. In DIAN--OBS compared to the literature group the rate of spasticity was not significantly different (10/107, (9·3%) vs. 113/753 (15%), p= 0·12). The rate of behavioral and personality changes was greater in the DIAN--OBS group compared to the literature group (65/107 (61%) vs. 239/753 (32%), p \< 0·0001), but hallucinations were similar and low (7/107 (7%) vs. 42/753 (6%), p= 0·69) in both groups. No individuals in the DIAN--OBS cohort have reported recent or active hemorrhagic stroke or ischemic stroke whereas the rate from the reported literature was low (55/753, 7·3%).

We also examined the prevalence of behavioral and neurological symptoms in the reported literature, by mutated gene. In order to account for other genetic factors specific to the family and physiological changes as an individual ages, pedigree ID and age of onset were included as covariates ([figure 2](#F2){ref-type="fig"}). The number of *PSEN2* mutation carriers was too small to make meaningful comparisons when these covariates are taken into consideration. Compared to APP mutation carriers, *PSEN1* mutation carriers as reported by published literature are significantly more likely to exhibit myoclonus (OR = 4·25, 95% CI \[1·37, 13·2\], p = 0·0125), corticobulbar deficits (OR = 9·78, 95% CI \[1·32, 72·4\], p = 0·0257), and aphasia (OR = 3·76, 95% CI \[1·33, 10·7\], p = 0·0129); spasticity was also more common in PSEN1 mutation carriers (n=110 of 547) compared to APP mutation carriers (n=2 of 171). On the other hand, *APP* mutation carriers were significantly more likely to present with ischemic stroke (OR = 3·92, 95% CI \[1·33, 11·6\], p = 0·0135); a hemorrhagic stroke was also more common APP mutation carriers (n=29 of 171) compared to PSEN1 mutation carriers (n=2 of 547). There were no significant differences in the prevalence of parkinsonism, apraxia, visual agnosia, behavioral/personality changes, or hallucinations between the three groups in the literature. In contrast, there were no significant differences in the DIAN cohort in myoclonus, aphasia, or stroke.

Clinical stage of disease was also associated with an increased frequency of all clinical features, with the exception of corticobulbar deficits, with increasing disease severity as measured by CDR--SB) in the DIAN--OBS ([figure 3b](#F3){ref-type="fig"}).

Age at symptom onset was significantly associated with an individual's likelihood of presenting with several symptoms in the literature cohort. Older age at onset is associated with elevated rates of ischemic stroke (p = 0·0003, OR for developing symptom = 1·09 per 1-year increase in age of onset, 95% CI \[1·04, 1·14\]) and decreased rates of myoclonus (p = 0·0007, OR = 0·93, 95% CI \[0·90, 0·97\]), seizures (p = 0·0018, OR = 0·95, 95% CI \[0·92, 0 ·98\]), corticobulbar deficits (p = 0·0012, OR = 0·91, 95% CI \[0·86, 0·96\]), and cerebellar ataxia (p = 0·0002, OR = 0·82, 95% CI \[0·74, 0·91\]) ([figure 3](#F3){ref-type="fig"}).

For the DIAN--OBS cohort, prevalence rates were only calculated for *PSEN1* and *APP*, as there were too few symptomatic individuals with *PSEN2* mutations. After excluding Dutch mutation carriers, several symptoms were notably absent from APP mutation carriers in the DIAN--OBS population: new-onset seizures, stroke, and corticobulbar deficits.

Finally, we compared *PSEN1* mutation carriers before and after codon 200 in the DIAN--OBS and literature groups, and compared the rates at which they demonstrated behavioral and neurological deficits ([figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). In the literature group, *PSEN1* mutations after codon 200 were more likely to be associated with spasticity (21/215 (9·8%) vs. 89/332 (26·8%), p \< 0·0001). However, in the DIAN--OBS cohort, there was no significant difference in the prevalence of any symptom for mutations before or after codon 200. Interestingly, mirroring recent findings by Ryan et al,^[@R5]^ the pre-codon 200 population in the DIAN--OBS cohort has a significantly earlier age of onset than the post-codon 200 population (37·3[(]{.ul}6.9) vs. 45·0[(]{.ul}8·1), p \< 0·0001), a difference that was not seen in the literature population (42·8[(]{.ul}10·4) vs. 43·7[(]{.ul}8·3), p = 0·319).

Discussion {#S13}
==========

In the DIAN--OBS, we found that the most frequently reported non-amnestic manifestations were cognitive, including visual agnosia, aphasia, and behavioral changes. However, in our meta-analysis of the literature, we found moderate rates of motor symptoms and seizures and lower rates in the DIAN--OBS. Interestingly, younger age of onset and more advanced stages of disease were related to a higher frequency of non-cognitive clinical features. A larger prospective cohort study now reports that a significant minority, 16% of the individuals with ADAD had non-amnestic cognitive phenotypes and about 25% had atypical neurologic symptoms in addition to an amnestic phenotype \[Ryan et. Al 2016 Lancet Neurology\], suggesting that in cases with unusual neurologic manifestations, genetic counseling and testing may be warranted.

One potential interpretation of these findings is that compared to clinical data collected prospectively in DIAN--OBS, case reports may overestimate the prevalence of non-cognitive neurologic manifestations (eg, myoclonus and seizures), while underestimating cognitive neurologic manifestations (eg, visual agnosia, aphasia, and behavioral/personality changes). Two sources of bias that could contribute include measurement bias and ascertainment bias. The DIAN--OBS prospective cohort study complements the literature reports to help account for these biases. Likewise, the literature reports provide a broader understanding with longer duration follow-up and more advanced disease.

With regards to measurement bias, our study demonstrates the impact of having systematic protocols in observational cohort studies ([supplemental table 1](#SD1){ref-type="supplementary-material"}). By employing uniform study procedures, symptoms are consistently identified, such as non-amnestic cognitive symptoms. The DIAN--OBS prospective and uniform assessments of earliest symptom onset may account for the earlier age of onset reported in the DIAN--OBS cohort. However, the limited follow up period in DIAN--OBS compared to literature likely resulted in a lower prevalence of certain symptoms such as seizures and myoclonus that were found to be higher in the published literature cohort, due to higher symptom prevalence at later stages of the disease ([figure 3b](#F3){ref-type="fig"}). With further follow-up, the DIAN--OBS will be positioned to accurately prospectively measure symptoms with more advanced disease.

Non-amnestic cognitive phenotypes are more commonly reported in SAD and include language variants, executive-frontal variants and a visuoperceptual variant- *posterior cortical atrophy* (PCA)^[@R13]^. In general, these focal variants have been reported less, in ADAD^[@R14],[@R15]^. Importantly, in SAD these variants appear to occur more frequently at younger ages of onset. A recent study found an odds ratio of greater than 5--12 for non-amnestic cognitive impairment in those with AD in the 6th decade versus those in the 9th decade.^[@R16]^ Similar to the common SAD presentation in DIAN-OBS the majority of subjects had amnestic impairments as the first presenting symptom^[@R2]^.

The current literature indicates that when non-amnestic variants are present, the symptoms are related to NFT pathology and not Aβ plaques^[@R17]^. Thus, in both SAD and DIAD, clinical cognitive symptoms appear to be more related to tau pathology^[@R18]^.

We sought to determine the age, disease stage, mutation, and other genetic effects on the manifestation of symptoms. Interestingly, age of onset appears to significantly impact the risk of neurologic manifestations. For example, in the literature cases, individuals who begin to decline at a younger age are more likely to develop myoclonus and seizures than their older age at onset counterparts. In contrast, stroke and hemorrhage were associated with older ages of onset.

However, the DIAN--OBS cohort showed lower overall incidences of myoclonus and seizures than the literature group, possibly due to milder stages of disease ([figure 3b](#F3){ref-type="fig"}). In the DIAN-OBS study, we found a trend of increasing prevalence of all symptoms including cognitive symptoms such as apraxia, visual agnosia, and non-cognitive symptoms including such as seizures, myoclonus, spasticity, cerebellar ataxia, and parkinsonism, at later stages of disease. Several previous studies suggest that for individuals with ADAD, seizures are correlated with earlier age of onset and more severe disease^[@R19]-[@R23]^. Our work focusing on the published literature supports the importance of the age of onset as it relates to myoclonus and seizures, and now adds the association of disease duration and symptom frequency from the DIAN--OBS. In the sporadic Alzheimer population, there is also evidence to support that an earlier age of onset is associated with an increased risk of seizures^[@R24],[@R25]^.

In order to account for other genetic or environmental factors that may influence disease presentation within a pedigree, we included family membership as a covariate in our analysis of symptom prevalence in *PSEN1, PSEN2*, and *APP* mutation carriers as reported in the literature. We demonstrated some differences between *APP, PSEN1*, and *PSEN2* mutations in the prevalence of certain symptoms (eg, in myoclonus and spasticity for *PSEN1*). Further, we found a propensity for APP mutation carriers to present with stroke or hemorrhage. It has been previously reported that *PSEN1* mutations before codon 200 are pathologically different from those after codon 200, likely due to differences in the severity of amyloid angiopathy and rates of amyloid deposition^[@R26]^. However, aside from spasticity, there are no apparent differences in symptom prevalence between *PSEN1* pre-codon 200 and post-codon 200 mutations ([figure 4](#F4){ref-type="fig"}). Significant heterogeneity exists within the pre- and post-codon 200 *PSEN1* mutation groups. Additionally, within *PSEN1*, there is a notable paucity of pathogenic mutations between codon 290-350 ([figure 5](#F5){ref-type="fig"}), which gives rise to three possibilities -- that mutations in this region are asymptomatic, that they are lethal, or that these regions have intrinsically lower rates of mutation.

Although APOE ε4 is a major risk factor for SAD^[@R27]^, the evidence for APOE's effect on ADAD presentation is less clear^[@R7],[@R28]-[@R30]^. Our current analysis of symptomatic mutation carriers is too small for constructing a model that includes APOE status as a co--variate in addition to age of onset, pedigree membership, and mutated ADAD gene.

The strength of the DIAN Observational Study is that it is a prospective cohort study of many mutations and families implemented with uniform standard assessments. However, limitations of the DIAN--OBS include the relatively small number of symptomatic participants, with 107 individuals in various stages of dementia as determined by our inclusion criteria. Consequently, we could not construct a model that simultaneously takes into account factors that may influence disease course such as mutated gene, duration of follow up, and *APOE* genotype. Further, the DIAN--OBS dataset includes few severe stages of disease with the average stage at moderate dementia (mean MMSE 21.0 (10.9)).

Accurately determining the prevalence of specific clinical and neurological signs and symptoms is important for defining a clinical disease, understanding its prognosis and impact on patients, and for informing the conduct of clinical research. A more complete understanding of cognitive and other neurological manifestations of ADAD will allow for improvements in diagnosis, prognosis, and management, as well as the design of research studies in this unique and important population. Future studies will be able to compare the clinical presentation of ADAD patients with sporadic Alzheimer's disease in greater detail, leading the field toward a deeper understanding of their shared clinical manifestations which will be critical to accurately interpret the findings of ongoing treatment trials in each disorder.
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ADAD

:   autosomal dominant Alzheimer's disease

APOE

:   Apolipoprotein E

APP

:   amyloid precursor protein

CAA

:   Cerebral amyloid angiopathy

CDR

:   Clinical Dementia Rating

DIAN

:   Dominantly Inherited Alzheimer's Network

DIAN-OBS

:   DIAN Observational Study

FAQ

:   Functional Activities Questionnaire

GDS

:   Geriatric Depression Scale

HIS

:   Hachinski Ischemic Score

MMSE

:   Mini-Mental Status Exam

PSEN1

:   presenilin-1

*PSEN2*

:   presenilin-2

UPDRS

:   Unified Parkinson's disease rating scale

UDS

:   Uniform Data Set

![Combined symptom prevalence in reported and prospectively observed ADAD\
Included are all individuals with detailed clinical descriptions from the DIAN prospective observational study and the ADAD literature (N = 107 and 753, respectively). Error bars are 95% confidence intervals.](nihms-827342-f0001){#F1}

###### Comparison of reported symptom prevalence in APP, PSEN1, and PSEN2 mutation carriers

(Literature - N = 171 for *APP*, 547 for *PSEN1*, 35 for *PSEN2*; DIAN-OBS - N = 19 (*APP*), 86 (*PSEN1*), 2 (*PSEN2*)). Rates for *PSEN2* carriers in DIAN-OBS were not calculated as there were only two symptomatic individuals in that group. Although significant variability in symptom prevalence is observed between mutations in the three genes in the reported literature, there were few differences between *APP* and *PSEN1* in the DIAN-OBS cohort. Error bars shown are 95% confidence intervals.
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![a. Comparison of reported prevalence of cognitive and non-cognitive neurological symptoms in ADAD by age of disease onset. Individuals were considered symptomatic if they developed the symptom at any point in their disease course. Solid lines represent symptoms for which a one-year increase in age of onset is associated with a statistically significant change in risk.\
b. Symptom prevalence by CDR Sum of Box score, in DIAN-OBS. All cognitive symptoms and most non-cognitive symptoms (except corticobulbar deficits) increase in prevalence as the clinical stage worsens. Total CDR-SB = CDR sum of boxes + supplemental sum of boxes, possible scores 0-24. As all individuals included in the DIAN-OBS analysis are symptomatic, the lowest total CDR-SB in this group is 0.5.](nihms-827342-f0004){#F3}

###### Comparison of symptom prevalence for PSEN1 mutations before and after codon 200 in literature and DIAN-OBS cohort

(Literature - N = 215, 332; DIAN-OBS - N = 24, 62).

![](nihms-827342-f0005)

![](nihms-827342-f0006)

###### Distribution of known pathogenic *PSEN1* mutations in literature and the rates at which carriers demonstrated spasticity in their disease course

![](nihms-827342-f0007)

![](nihms-827342-f0008)

###### Study population

  -------------------------------------------------------------------------
                                         Literature   DIAN    
  ----------------------- -------------- ------------ ------- -------------
  **N**                   Total          1228         107     

                          Clinical\      753          107     
                          descriptions                        

  **Sex**                 M              34·7%        43·9%   

                          F              38·0%        56·1%   

                          Unknown        27·3%        \-      

  **Gene**                *PSEN1*        74·2%        80·4%   

                          *PSEN2*        5·0%         1·9%    

                          *APP*          20·8%        17·7%   

  **Age of symptom**\                                         p = 0·0004
  **onset**                                                   

  Mean                    46·0           42·9                 

                          SD             10·5         8·17    

  **Follow up (years)**   Mean           8·33         3·93    p \< 0·0001

                          SD             4·59         3·18    

  **CDR**                 Mean           \-           1·05    

                          SD             \-           0·79    

  **CDR-SB**              Mean           \-           5·39    

                          SD             \-           5·06    

  MMSE                    Mean           \-           20.98   

                          SD             \-           10.92   
  -------------------------------------------------------------------------

###### Comparisons of symptom prevalence between DIAN and Literature

  ------------------------------------------------------------------------------------------------------
                              Frequency\   95% CI            Frequency\     95% CI            p-value
                              (DIAN)                         (Literature)                     
  --------------------------- ------------ ----------------- -------------- ----------------- ----------
  **Parkinsonism**            0·11         \[0·053, 0·17\]   0·12           \[0·10, 0·15\]    0·71

  **Myoclonus**               0·094        \[0·038, 0·15\]   0·19           \[0·17, 0·22\]    0·012

  **Seizures**                0·028        \[0, 0·059\]      0·20           \[0·17, 0·23\]    \<0·0001

  **Spasticity**              0·094        \[0·038, 0·15\]   0·15           \[0·12, 0·18\]    0·12

  **Corticobulbar**\          0·028        \[0, 0·059\]      0·081          \[0·06, 0·10\]    0·051
  **deficits**                                                                                

  **Cerebellar ataxia**       0·149        \[0·082, 0·22\]   0·031          \[0·018,\         \<0·0001
                                                                            0·043\]           

  **Aphasia**                 0·53         \[0·44, 0·63\]    0·23           \[0·20, 0·26\]    \<0·0001

  **Apraxia**                 0·075        \[0·025, 0·12\]   0·12           \[0·094, 0·14\]   0·19

  **Visual agnosia**          0·55         \[0·46, 0·65\]    0·056          \[0·039,\         \<0·0001
                                                                            0·072\]           

  **Hallucinations**          0·065        \[0·019, 0·11\]   0·056          \[0·039,\         0·69
                                                                            0·072\]           

  **Behavior/Personality**\   0·61         \[0·51, 0·70\]    0·32           \[0·28, 0·35\]    \<0·0001
  **changes**                                                                                 

  **Hemorrhagic**\            0            \-                0·041          \[0·027,\         \-
  **stroke**                                                                0·055\]           

  **Ischemic stroke**         0            \-                0·042          \[0·028,\         \-
                                                                            0·057\]           

  **N**                       **107**                        **753**                          
  ------------------------------------------------------------------------------------------------------

###### Research in context

Evidence before this study {#S15}
==========================

We reviewed publications up through January 27, 2015 cited in the AD/FTD Mutation Database and the Alzheimer Research Forum database, and searched PubMed identifying 189 peer-reviewed journal articles which reported individual-level data on age of symptom onset, disease course from onset to death, and the presence of fourteen neurological findings previously reported to be associated with ADAD. There is a large body of literature providing phenotypic information on specific autosomal dominant Alzheimer disease (ADAD) mutations. Over 170 of these reports are on a small number of subjects or families across a wide spectrum of clinical severity. These reports suggested a relatively high prevalence of non-cognitive neurologic manifestations including behavioral, motor symptoms, and seizures which may be further influenced by specific gene mutation. However, there are less than 7 reports of large cohorts from single centers and no compiled individual level data review.

Added value of this study {#S16}
=========================

Our literature based dataset includes 1228 affected individuals from literature reports, with detailed clinical descriptions of disease course available for 753 of this group with an average of 8 years of follow-up. The DIAN-OBS dataset included 107 symptomatic individuals with detailed clinical data from an ongoing, observational study with an average of over 3 years of follow-up. From these two datasets we were able to report descriptive statistics, comparisons of prevalence between the DIAN study and the published data base, as well as determine correlations between clinical features and gene mutation type and position in both data sets. This study provides one of the largest and most diverse collections of prospectively followed, symptomatic, ADAD populations to provide more accurate estimates of non-amnestic clinical features.

With the large number of *PSEN1* mutations we were also able to explore whether atypical clinical features were more commonly associated with specific codon position, as has been suggested previously. However, in the DIAN population we found no clear associations of clinical features with *PSEN1* codon position.

Implications of available evidence {#S17}
==================================

This study indicates that the prevalence of atypical clinical features in ADAD is low and may have been overestimated in the published literature. Non-cognitive neurologic symptoms of AD appear to affect the minority of ADAD mutation carriers, suggesting that the mutations are not the major factor for presentation of non-cognitive neurologic manifestations of AD. The factors that influence the presence of neurological symptoms include unidentified genetic and environmental factors with some impact from the age of onset, stage of disease and type of mutation. Further, non-amnestic cognitive impairment is common in ADAD, similar to sporadic AD. As ADAD has provided a wealth of understanding of AD pathophysiologic processes, future work comparing ADAD with sporadic AD will lead to a better understanding of both sporadic and dominantly inherited AD.

In our analysis, we recorded each individual as exhibiting a symptom if the manuscript in which they are found mentioned the symptom in connection with dementia in a detailed clinical description of the course of disease. For DIAN, some of these symptoms are covered by single variables in the UDS ([supplemental table 1](#SD1){ref-type="supplementary-material"}), such as parkinsonism, seizures, visual agnosia, aphasia, and stroke, while others were derived from a combination of several variables, such as hallucinations (combined visual and auditory), cerebellar ataxia (abnormal finger-nose-finger and/or heel-shin exam, or clinical report), and behavioral changes (disinhibition, agitation, irritation, and other personality changes). A third group (myoclonus, spasticity, corticobulbar deficits, and apraxia) did not have specific variables associated but were tested and searched for in the neurological exam conducted during each visit and the UPDRS (UDS B3). Differences in how variables are obtained present a challenge to interpretation, as symptoms specifically enumerated in the UDS may be more consistently detected and documented by clinicians. This appears to be the case for visual agnosia and behavioral/psychiatric changes, which are common in both sporadic and dominantly inherited Alzheimer's disease ([figure 1](#F1){ref-type="fig"}). The language used in the UDS may also influence the rate of detection. For instance, aphasia in the DIAN group is determined using UDS B9 4c, which is a clinician judgment of symptoms including "hesitant speech, trouble finding words, and using inappropriate words without self correction", all of which may reflect word-finding difficulty which can be a consequence of memory impairment. Alternatively, the more stringent category of primary progressive aphasia is included as a possible clinician diagnosis (UDS D10), but so far there has not been a case documented as such in the DIAN cohort as of December 2014. Consequently, the higher prevalence of aphasia in the DIAN population may be an artifact of how the UDS question is constructed. Likewise, in the published literature it is likely that the predominant symptom at the time of clinical presentation is most likely to be reported. This would result in a tendency to under report symptoms such as language disorders, which are very common with disease progression in all forms of Alzheimer's disease.
